VioQuest Pharmaceuticals Doses First Patient In Phase I/IIa Clinical Trial With VQD-002 (Triciribine-Phosphate) For Treatment Of Leukemia

... VioQuest Pharmaceuticals, Inc. (OTC Bulletin Board: VQPH), a New Jersey-basedbiopharmaceutical company, announced that it has dosed the first patient inits Phase I/IIa clinical trial of VQD-002, triciribine-phosphate (TCN-P) atthe University of Texas MD Anderson Cancer Center. Dr. [click link for full article] ...